24/7 Market News Snapshot 29 January, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

January 29, 2025

DENVER, Colo., 29 January, 2025 (247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp is experiencing significant market momentum, with shares opening at $2.17 and rising to approximately $1.997, marking an impressive increase of around 47.93% from the prior day’s closing price of $1.35. This surge has generated considerable trading activity, evidenced by a current volume of 103.92 million shares, reflecting heightened investor interest and a potentially bullish market sentiment around the company.

This surge coincides with recent landmark developments in Silexion’s precision oncology initiatives, particularly the positive preclinical data for its therapeutic candidate, SIL-204. Key findings indicate a striking 50% reduction in tumor growth and complete necrosis in half of the treated tumors within 30 days post-treatment. Notably, therapeutic levels of SIL-204 have been sustained for over 56 days following a single systemic administration, effectively targeting crucial KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D.

These advancements come at a time of growing demand for innovative oncology solutions, as illustrated by major industry acquisitions, such as Pfizer’s $43 billion purchase of Seagen and AbbVie’s $10.1 billion acquisition of Immunogen. Silexion’s RNA interference-based therapy offers a unique approach, distinguishing it from traditional small molecule inhibitors. With favorable results from Phase 2 trials of its first-generation LODER™ platform, Silexion is poised for clinical trials of SIL-204, focusing on its efficacy against KRAS-driven cancers.

Analysts are bullish, with Maxim Group initiating coverage on Silexion and issuing a “strong buy” recommendation alongside a revised price target of $9. As Silexion Therapeutics moves forward, stakeholders are keenly attentive to forthcoming developments that could shape its trajectory within the precision oncology sector.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.